Jacques‐Olivier Bay

Author

Jacques‐Olivier Bay

Centre Jean Perrin

Also Known As

Bay, Jacques-Olivier, J. Bay, J.-O. Bay, J.O. Bay, Jacques-Olivier Bay, Jacques‐Olivier Bay

Publications

Citations

H-Index

Concepts

All Affiliations

Centre Jean Perrin Centre Hospitalier Universitaire de Clermont-Ferrand Inserm Centre Léon Bérard Institut Gustave Roussy

About

Jacques‐Olivier Bay is an author at Centre Jean Perrin specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	184
2	Health Sciences	1	1	15
3	Cell Biology	1	1	19
4	Diagnostic Sciences	1	1	15
5	Immunology	1	1	19

Jacques‐Olivier Bay

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study Nicolas Penel, Binh Bui, Jacques‐Olivier Bay, Journal of Clinical Oncology	2008	683
Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial Isabelle Laure Ray-Coquard, Julien Dômont, Emmanuelle Tresch‐Bruneel, Journal of Clinical Oncology	2015	188
Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO) Isabelle Ray‐Coquard, Antoîne Italiano, Emmanuelle Bompas, The Oncologist	2012	187
Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis Sylvie Négrier, David Pérol, Alain Ravaud, Cancer	2007	181
Sorafenib in patients with progressive epithelioid hemangioendothelioma Christine Chevreau, Axel Le Cesne, Isabelle Ray‐Coquard, Cancer	2013	120
Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome Nicolas Penel, Antoîne Italiano, Isabelle Ray‐Coquard, Annals of Oncology Surgical OncologyMedicinePathologyWeekly PaclitaxelSurgery	2011	112
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial Roch Houot, Emmanuel Bachy, Guillaume Cartron, Nature Medicine	2023	84
Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first‐line treatment Didier Blaise, Jean Michel Boiron, Catherine Faucher, Cancer	2005	56
High incidence of cancer in a family segregating a mutation of theATM gene: Possible role of ATM heterozygosity in cancer Jacques‐Olivier Bay, Nancy Uhrhammer, D Pernin, Human Mutation	1999	29
Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial Nicolas Penel, Isabelle Ray‐Coquard, Christine Bal-Mahieu, Targeted Oncology AngiogenesisLow LevelVascular SarcomasMedicineVascular Surgery	2013	25

Page 1